Product Code: DMKC0131939
Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs. Currently, the treatment of melanoma has a limited budgetary impact and Datamonitor Healthcare does not anticipate any immediate impact on the pricing of melanoma therapies. However, in the future, manufacturers may have to consider novel pricing arrangements for high-cost combination treatments.
This report addresses the following questions:
- What are the main utilization management tools used by US payers for melanoma drugs and how will their use evolve in the future?
- How concerned are the US payers regarding the growing budget impact of melanoma therapies?
- Which melanoma drugs were the most successful in European health technology assessments and why?
- In which countries are melanoma drugs reimbursed under risk-sharing agreements?
- What levers are most commonly used by EU payers to limit the budget impact of melanoma therapies?
TABLE OF CONTENTS
- 1. Market entry of new drugs will dramatically increase the budget impact of melanoma Treatments
- 2. Marketed malignant melanoma products in the US, Japan, and five major EU markets
- 3. Pipeline malignant melanoma treatments in late-stage development
- 4. Price assumptions
- 5. Bibliography
- 6. Pricing
- 7. Reimbursement
- 8. Bibliography
- 9. Successful pricing outcomes hinge on receipt of a pricing premium
- 10. Nivolumab was awarded a 60% innovation margin
- 11. Bibliography
FIVE MAJOR EU MARKETS
- 12. Pricing
- 13. Reimbursement and health technology assessment
- 14. Bibliography